Combined anti-VEGF approach in neovascular glaucoma: clinical outcomes of intracameral and intravitreal bevacizumab administration
Open Access
- 18 April 2026
- journal article
- research article
- Published by Springer Nature in BMC Ophthalmology
- Vol. 26 (1)
Abstract
To evaluate short-term clinical outcomes of combined intracameral and intravitreal bevacizumab administration in patients with neovascular glaucoma (NVG),Keywords
This publication has 29 references indexed in Scilit:
- Medical and surgical management of neovascular glaucomaCurrent Opinion in Ophthalmology, 2025
- Comparative efficacy and safety of different anti-VEGF agents combined with different delivery methods for neovascular glaucoma: a systematic review and Bayesian network meta-analysisBMJ Open, 2024
- Neovascular Glaucoma: An UpdateKlinische Monatsblätter für Augenheilkunde, 2022
- A systematic review and meta-analysis of randomised controlled trials in the management of neovascular glaucoma: absence of consensus and variability in practiceGraefe's Archive for Clinical and Experimental Ophthalmology, 2022
- Comparisons of the short-term effectiveness and safety of surgical treatment for neovascular glaucoma: a systematic review and network meta-analysisBMJ Open, 2022
- Management of Neovascular Glaucoma With Panretinal Photocoagulation, Intravitreal Bevacizumab, and Subsequent Trabeculectomy With Mitomycin CJournal of Glaucoma, 2010
- Intravitreal Bevacizumab for Neovascular GlaucomaJournal of Glaucoma, 2009
- Intracameral Bevacizumab (Avastin) for Neovascular GlaucomaJournal of Glaucoma, 2009
- Neovascular Glaucoma: Etiology, Diagnosis and PrognosisSeminars in Ophthalmology, 2009
- Bevacizumab (Avastin) for the treatment of neovascular glaucomaClinical & Experimental Ophthalmology, 2007